Pediococcus acidilactici (Lactobacillaceae) Lactic Acid Probiotic Bacterium

Pediococcus acidilactici is a Gram positive, facultatively anaerobic lactic acid bacterium, widely recognized as a safe and effective probiotic. It is most notably used as a zootechnical feed additive to stabilize gut flora in livestock and poultry, and as a potent producer of pediocin, a bacteriocin with broad spectrum antimicrobial activity. Modern genomic research has validated its resilience under gastrointestinal conditions and identified unique features such as a functional CRISPR Cas system in certain strains, while ongoing clinical trials are exploring its emerging potential as a postbiotic to mitigate metabolic syndrome in humans.

---

1. Taxonomic Insights

Species: Pediococcus acidilactici (Lindner, 1887)

Family: Lactobacillaceae

The Lactobacillaceae family comprises a diverse group of lactic acid bacteria, including the genera Lactobacillus, Pediococcus, and Weissella. These organisms are characterized by their ability to ferment carbohydrates primarily into lactic acid, are catalase negative, and are generally recognized as safe. The genus Pediococcus is distinguished by cells that divide in two planes, forming tetrads, unlike the rod shaped morphology of Lactobacillus.

Taxonomic Note: The species was originally described as Pedicoccus acidilactici and has been extensively studied under that name. It is often confused with Pediococcus pentosaceus, but whole genome sequencing has allowed for precise differentiation between these closely related species. Strain P10, a novel isolate from Iranian broiler chickens, was confirmed as P. acidilactici with 99.57% genome similarity .

Related Species from the Same Family:

· Pediococcus pentosaceus: A closely related species widely used as a starter culture in food fermentation, particularly for meat and vegetable products. It shares similar probiotic potential and bacteriocin production capabilities.

· Lactobacillus acidophilus: One of the most well known probiotic species, used extensively for human gastrointestinal health, immunomodulation, and vaginal health.

· Lacticaseibacillus rhamnosus GG: A extensively studied probiotic strain with documented benefits for diarrhea prevention, immune support, and dental health.

· Enterococcus faecium: Another lactic acid bacterium used as a probiotic and feed additive, often co formulated with Pediococcus in commercial products for synergistic effects.

---

2. Common Names

Scientific Name: Pediococcus acidilactici | Common Trade Names: Bactocell, pA1c, Pediocin producer | Feed Additive Designations: CNCM I 4622, DSM 33758 | Strain Specific Names: P10, SY21, SY22, PA 1 | Product Names: Biomin C5 (multi strain blend including P. acidilactici) | Postbiotic Formulation: pA1c®HI

---

3. Medicinal Uses

Primary Actions: Probiotic, Gut flora stabilizer, Antimicrobial (bacteriocin production), Immunomodulatory, Antidiarrheal, Antiviral (CRISPR mediated defense).

Secondary Actions: Anticancer (potential via bacteriocins), Anti-inflammatory, Antihyperglycemic (postbiotic effects), Cholesterol lowering, Antipathogenic.

Active Substances (Metabolites):

· Pediocin (PA 1): The signature bacteriocin, a small antimicrobial peptide with potent activity against Listeria monocytogenes and other Gram positive pathogens.

· Pediocin like Bacteriocins: Multiple putative bacteriocin encoding genes identified in strain P10.

· Postbiotic Metabolites: Short chain fatty acids, exopolysaccharides, and other soluble factors produced during fermentation.

---

4. Key Bioactive Compounds and Their Action

· Pediocin PA 1 (Bacteriocin): The most extensively characterized antimicrobial peptide produced by P. acidilactici. It belongs to the Class IIa bacteriocins. Its actions include Antimicrobial activity against pathogenic Gram positive bacteria, particularly Listeria monocytogenes. The peptide targets the cell membrane of susceptible bacteria, creating pores and leading to cell death. It is Thermostable and active over a wide pH range. The presence of a C terminal disulfide bridge in pediocin PA 1 broadens its antimicrobial spectrum and renders its activity less temperature dependent compared to other bacteriocins .

· Probiotic Cellular Components (Lipoteichoic acid, Peptidoglycan): These surface molecules interact with pattern recognition receptors on intestinal epithelial cells, mediating Immunomodulatory effects.

· CRISPR Cas System (Type II A): A complete and functional CRISPR Cas adaptive immune system identified in the genome of P. acidilactici strain P10. It encodes cas9, cas1, cas2, and csn2 genes, and contains 20 unique spacer sequences, 17 of which match known bacteriophage genomes. This system provides Antiviral defense and enhances the strain's resilience in complex microbial environments .

· Postbiotic Metabolites (pA1c®HI): Soluble factors produced during bacterial growth that are being investigated for Metabolic benefits. In a 2026 clinical trial, the postbiotic pA1c®HI is being evaluated for its ability to improve metabolic disturbances including cholesterol, triglycerides, blood glucose, insulin resistance (HOMA IR), and HbA1c in patients with psychosis treated with antipsychotic drugs .

---

5. Traditional and Modern Applications

Animal Feed Additive (Gut Flora Stabilizer)

Formulation: Viable cells of P. acidilactici as a dry powder or coated granules.

Application: Incorporated into complete feed or drinking water for poultry, pigs, fish, and crustaceans.

Dosage: Minimum of 1 x 10^9 CFU/kg feed or 5 x 10^8 CFU/L water for poultry; 1 x 10^9 CFU/kg feed for all porcine species, avian species, fish, and crustaceans .

Reasoning: P. acidilactici stabilizes the gut microbiota by inhibiting pathogenic bacteria through bacteriocin production and competitive exclusion. It improves intestinal health, enhances feed conversion efficiency, and reduces the need for antibiotic growth promoters. The European Food Safety Authority has concluded that P. acidilactici CNCM I 4622 has the potential to be efficacious as a zootechnical additive for poultry and other species .

Food Biopreservation

Formulation: Pediocin producing cultures or purified pediocin.

Application: Added to meat, dairy, and vegetable products to inhibit spoilage and pathogenic bacteria.

Reasoning: Pediocin is a natural antimicrobial that extends shelf life and enhances food safety by controlling Listeria monocytogenes and other foodborne pathogens. It is thermostable and remains active over a wide pH range, making it suitable for various food matrices .

Human Probiotic and Postbiotic Interventions

Formulation: Viable probiotic cultures or postbiotic preparations (pA1c®HI).

Application: Orally administered capsules or sachets.

Clinical Status: A 2026 double blind, placebo controlled trial (GLUCOPSICO) is investigating the postbiotic pA1c®HI as an add on to antipsychotic drugs for metabolic syndrome in first episode psychosis and schizophrenia spectrum disorders. The study monitors glucose via continuous sensors, analyzes gut microbiota metatranscriptome, and measures changes in cholesterol, triglycerides, glucose, insulin, HOMA IR, and HbA1c over 12 weeks .

Reasoning: This represents a novel application moving beyond viable probiotics to use soluble postbiotic metabolites for systemic metabolic benefits, potentially mitigating the weight gain and metabolic disturbances induced by antipsychotic medications.

---

6. Safety Assessment and Regulatory Status

GRAS Status: Pediococcus acidilactici is generally recognized as safe for use in food and feed.

Hemolytic Activity: High quality probiotic strains are non hemolytic (gamma hemolytic). Strain P10 and strains SY21/SY22 show no lysis of red blood cells .

Antibiotic Resistance: P. acidilactici exhibits intrinsic resistance to certain antibiotics such as vancomycin, which is a inherent characteristic of the genus and not transferable. A 2025 safety assessment of strains SY21 and SY22 confirmed that antibiotic resistance exceeding EFSA cut off values (kanamycin and clindamycin) was intrinsic, with no transferable resistance genes detected via whole genome sequencing .

Bile Salt Hydrolase Activity: Safe probiotic strains do not exhibit deconjugation of bile salts, which can interfere with fat metabolism. Strains SY21 and SY22 tested negative for bile salt hydrolase activity .

Biogenic Amine Production: Safe strains do not produce biogenic amines (histamine, tyramine), which can cause adverse reactions. Strains SY21 and SY22 tested negative for biogenic amine production .

Cytotoxicity: Safe strains are non cytotoxic to intestinal epithelial cells such as Caco 2 cells .

Regulatory Authorizations: Pediococcus acidilactici CNCM I 4622 is authorized as a feed additive for all porcine species for fattening, all avian species, all fish species, and all crustaceans under EU Regulation 2020/151 .

---

7. Genomic and Functional Characterization of Strain P10

Overview

A landmark 2025 study published in Scientific Reports provided a comprehensive in vitro and whole genome characterization of Pediococcus acidilactici strain P10, isolated from Iranian broiler chickens. This study integrated traditional probiotic assays with cutting edge genomic analysis, revealing novel features not previously described in the species .

Probiotic Properties Validated Phenotypically and Genomically

· Acid Tolerance: Strain P10 showed high survival rates of 95% at pH 3 and 99% at pH 4 under simulated gastrointestinal conditions. Genomic analysis confirmed the presence of stress resistance genes associated with acid tolerance.

· Bile Salt Tolerance: The strain maintained a significant survival rate of 55% in the presence of 0.3% bile salts after 8 hours.

· Adhesion to Intestinal Cells: Microscopic analysis revealed strong adherence of P10 to Caco 2 intestinal epithelial cells, with corresponding adhesion genes identified in its genome.

· Antimicrobial Activity: P10 displayed robust broad spectrum antimicrobial activity against key pathogens including Escherichia coli, Salmonella enterica, Staphylococcus aureus, Listeria monocytogenes, and Pseudomonas aeruginosa, with inhibition zones exceeding 2 mm in diameter. This activity was underpinned by the identification of multiple putative bacteriocin encoding genes.

Unique Genomic Discoveries

· Complete Type II A CRISPR Cas System: The 1.84 Mb genome of P10 was found to harbor a complete, functional Type II A CRISPR Cas system. This system includes the core cas genes cas9, cas1, cas2, and csn2, indicating an active adaptive immune response capable of acquiring new spacers.

· Phage Defense: The CRISPR array contained 20 unique spacer sequences. Crucially, 17 of these spacers showed 100% identity to sequences within known bacteriophage genomes, confirming prior encounters with viral elements and providing robust antiviral defense.

· Unique Genetic Elements: Pan genomic analysis highlighted 59 genes unique to strain P10 that are not found in other P. acidilactici strains, suggesting novel metabolic and adaptive capabilities previously uncharacterized within the species.

Significance: Strain P10 represents a highly promising probiotic candidate for animal health and functional foods, combining confirmed resilience, antimicrobial action, and unique genomic advantages including its specialized CRISPR Cas system .

---

8. Pediocin: The Signature Bacteriocin

Structure and Classification: Pediocin PA 1 is a Class IIa bacteriocin, a small (approximately 4.6 kDa), heat stable, antimicrobial peptide produced by P. acidilactici. It is characterized by a conserved N terminal sequence YGNGV and a C terminal disulfide bridge in some variants.

Mechanism of Action: Pediocin targets the cell membrane of susceptible Gram positive bacteria. It binds to the mannose phosphotransferase system on the target cell surface, inserting into the membrane and forming pores. This leads to dissipation of the proton motive force, leakage of intracellular components, and ultimately cell death.

Antimicrobial Spectrum: Pediocin is particularly potent against Listeria monocytogenes, a dangerous foodborne pathogen. It also shows activity against Enterococcus faecalis, Clostridium perfringens, and Staphylococcus aureus.

C Terminal Disulfide Bridge: Research has shown that the presence of a C terminal disulfide bridge in pediocin like bacteriocins broadens the antimicrobial spectrum and renders the bacteriocin less temperature dependent. Introduction of this bridge into bacteriocins lacking it expands their target cell specificity and maintains potency at higher temperatures (37°C compared to 20°C) .

Applications: Pediocin is used as a natural food preservative (biopreservative) to extend shelf life and enhance safety of meat, dairy, and vegetable products. It also has potential therapeutic applications, including treatment of bacterial infections and even cancer .

---

9. Clinical Trial: Postbiotic for Metabolic Syndrome (GLUCOPSICO)

Trial Identification: NCT07371325, titled "Efficacy of Pediococcus Acidilactici as add on to Antipsychotic Drugs on Metabolic Syndrome Disturbances in First episode Psychosis and Schizophrenia Spectrum Disorders" .

Design: A double blind, placebo controlled, randomized, parallel assignment trial.

Population: 36 adult patients diagnosed with first episode psychosis or schizophrenia spectrum disorder who have received antipsychotic treatment for at least 8 weeks.

Intervention: The postbiotic pA1c®HI (derived from P. acidilactici) is administered as an add on to atypical antipsychotic medications.

Primary Outcome Measures (Metabolic Disturbances assessed at week 0 and week 12):

· Total cholesterol (mg/dL)

· LDL cholesterol (mg/dL)

· HDL cholesterol (mg/dL)

· Triglycerides (mg/dL)

· Plasma glucose (mg/dL)

· Insulin (µU/mL)

· Glycosylated hemoglobin (HbA1c %)

· HOMA IR index (insulin resistance)

Secondary Outcome Measures (Clinical symptoms):

· Positive and Negative Syndrome Scale (PANSS)

· Brief Negative Symptoms Scale (BNSS)

· Screening for Cognitive Impairment in Psychiatry (SCIP)

Innovative Features:

· This is the first study based on postbiotics instead of probiotics for this indication.

· The trial incorporates continuous glucose monitoring via sensors to track daily and weekly glucose levels.

· Gut microbiota metatranscriptome analysis from fecal samples is included to understand the mechanisms linking the postbiotic, microbiome, and metabolic function.

Significance: This trial represents a novel frontier for P. acidilactici, moving beyond traditional probiotic and feed additive applications into human metabolic health. If positive, it could provide a new therapeutic option for mitigating antipsychotic induced weight gain and metabolic syndrome, a major clinical challenge in psychiatric care .

---

10. An Integrated View of Healing with Pediococcus acidilactici

· For Animal Gut Health and Pathogen Control: P. acidilactici functions as a comprehensive gut stabilizer. The viable bacteria survive the gastrointestinal tract due to their acid and bile tolerance. Once established, they produce pediocin and other bacteriocins that directly inhibit pathogens like Listeria, Salmonella, and Clostridia. Their presence also stimulates the host immune system and competitively excludes harmful bacteria. This integrated action improves feed efficiency, reduces diarrhea, and decreases the need for antibiotic growth promoters in livestock and aquaculture.

· For Food Preservation (Biopreservation): Pediocin offers a natural alternative to chemical preservatives. Its thermostability and wide pH activity range make it suitable for diverse food matrices. It specifically targets dangerous pathogens like Listeria monocytogenes while being generally recognized as safe, enhancing both the shelf life and the safety of minimally processed foods.

· For Human Metabolic Health (Emerging Postbiotic Application): The 2026 GLUCOPSICO trial represents a paradigm shift, utilizing postbiotic metabolites rather than live bacteria. This approach harnesses the soluble factors produced by P. acidilactici to modulate host metabolism. The trial's focus on cholesterol, triglycerides, glucose, insulin resistance, and HbA1c targets the core components of metabolic syndrome, a growing global health concern. If successful, this could lead to a novel, safe adjunct therapy for patients on antipsychotic medications, potentially mitigating the serious metabolic side effects that contribute to cardiovascular morbidity.

· As a Source of Novel Probiotics and CRISPR Tools: The discovery of a complete Type II A CRISPR Cas system in strain P10 has dual significance. First, it enhances the strain's own robustness as a probiotic by providing adaptive immunity against bacteriophages. Second, the presence of cas9 opens possibilities for using this strain or its genetic elements in genome editing applications, expanding its utility beyond direct probiotic use.

Conclusion: Pediococcus acidilactici has evolved from a simple food fermentation bacterium to a versatile probiotic and biotechnological workhorse. Its signature bacteriocin, pediocin, is a cornerstone of natural food preservation. Its robust survival characteristics and safety profile have made it a globally authorized feed additive for improving animal health and productivity. The recent genomic discovery of a complete CRISPR Cas system in certain strains highlights the ongoing evolution of our understanding of this species. Most excitingly, ongoing clinical research is exploring its postbiotic metabolites as a novel therapeutic for metabolic syndrome in humans, representing a significant expansion of its potential applications. P. acidilactici stands at the intersection of traditional food science, modern probiotic development, and cutting edge metabolic medicine.

---

Disclaimer:

Pediococcus acidilactici is generally recognized as safe for use in food and feed based on extensive history and regulatory approvals. However, specific strain characteristics vary. Some strains may exhibit intrinsic resistance to certain antibiotics, which is not transferable and not a safety concern for typical use. Immunocompromised individuals should consult a healthcare provider before consuming live probiotic supplements. The postbiotic pA1c®HI is under clinical investigation and is not yet approved for general therapeutic use. Always use products as directed by manufacturers and healthcare professionals. This information is for educational purposes only and is not a substitute for professional medical advice.

---

11. Reference Books and Sources for In Depth Study:

· The Genera of Lactic Acid Bacteria by W.H.N. Holzapfel and B.J.B. Wood

· Bacteriocins of Lactic Acid Bacteria: Microbiology, Genetics, and Applications by Luc De Vuyst and Erick J. Vandamme

· Probiotics in Animal Nutrition: Production, Impact and Regulation by FAO

· Scientific Reports (2025) Volume 15, Article 28953 (P10 strain characterization)

· EFSA Journal (2025) Volume 23, Issue 5 (Biomin C5 efficacy)

· Food Science and Biotechnology (2025) Volume 34, Issue 14, Pages 3331-3340 (Safety assessment of SY21 and SY22)

---

12. Further Study: Probiotics and Bacteriocin Producers That Might Interest You

1. Pediococcus pentosaceus

· Species: Pediococcus pentosaceus | Family: Lactobacillaceae

· Similarities: The closest relative, sharing the tetrad forming morphology and probiotic potential. Both species are used as starter cultures and produce pediocin like bacteriocins. P. pentosaceus is more extensively used in vegetable and meat fermentation, while P. acidilactici is more prominent as a feed additive.

2. Lactococcus lactis

· Species: Lactococcus lactis | Family: Streptococcaceae

· Similarities: The classic producer of nisin, the most widely used bacteriocin in the food industry. Like P. acidilactici with pediocin, L. lactis is a workhorse for natural food preservation. Both organisms are Gram positive, catalase negative, and generally recognized as safe.

3. Lactiplantibacillus plantarum

· Species: Lactiplantibacillus plantarum | Family: Lactobacillaceae

· Similarities: A highly versatile and robust probiotic species with documented benefits for human gastrointestinal health, immune modulation, and cholesterol reduction. Like P. acidilactici, it produces multiple bacteriocins (plantaricins) and is used in food fermentations.

4. Bacillus subtilis

· Species: Bacillus subtilis | Family: Bacillaceae

· Similarities: A spore forming probiotic used extensively in animal feed and agriculture. Like P. acidilactici, it produces a diverse array of antimicrobial peptides and enzymes. The spore forming nature of Bacillus provides superior stability during feed processing compared to non spore forming lactic acid bacteria.

---

-x-x-x-End-x-x-x-